The components that treat, control, reduce, or alleviate inflammation include an analgesic for the DiGRA receptor,An acceptable salt, or an acceptable medicine. The ingredient may include an additional anti-inflammatory agent and may be designed for toxic applications, syringes, or implants. 1. It can be used in post-operative monitoring of eye pain to reduce the risk of adverse side effects with other therapeutic agents. 1. Requirement 1: including: (a) acceptable carrier of drugs； And (b) an analgesic for DiGRA,In order to treat, control, reduce or reduce the inflammation of patients, it is necessary to use effective quantity, or use acceptable medicament, or drug acceptable ester, It includes a compound whose formula is (1), in which a and Q are selected independently of the group consisting of arilo and heterosexual, cyclopropene and non cyclopropene that are not replaced and replaced, cyclopropene and non cyclopropene that are not replaced and replaced, cyclopropene and non cyclopropene that are not replaced and replaced, 1. Non substituted and substituted cyclopentyl and non cyclopentyl compounds, and non substituted and non periodic groups；R1 and R2 are independently selected from the group consisting of hydrogen, unsubstituted linear or branched C1-15 alkyl groups, substituted linear or branched C1-15 alkyl groups, unsubstituted C3-15 cycloalkyl groups, and substituted C3-15 cycloalkyl groups； R3 is one of the group consisting of hydrogen, unsubstituted linear or branched C1-15 alkyl groups, substituted linear or branched C1-15 alkyl groups, unsubstituted C3-15 cycloalkyl and heterocycloalkyl groups, substituted C3-15 cycloalkyl and heterocycloalkyl groups, groups aryl, heteroaryl groups, and heterocyclyl groups； B comprises a carbonyl, amino, divalent hydrocarbon group,E is water-based or amino； D does not exist or consists of a carbide NH group,it is life.Wherein R 'includes a set of linear or branched c1-15 tar without substitution or substitution； and R1
